John E. Harris, MD, PhD, is Professor and Chair of Dermatology at Massachusetts General Brigham (MGB) in Boston, MA. He serves as Director of the Vitiligo Clinic and Research Center, focusing both on the clinical management of vitiligo patients as well as research into new therapeutic strategies. His approach includes basic, translational, and clinical studies that incorporate the use of mouse models, human tissues, and small clinical trials that determine disease mechanisms of vitiligo, identify quantifiable markers of disease activity, and test new treatments. Previous work from his research team revealed that the IFN-g signaling pathway is central to both the progression and maintenance of vitiligo, and recent studies in both mice and humans have demonstrated efficacy of new immunotherapies that target this pathway. More recent data determined that IL-15 promotes maintenance of the disease, and targeting IL-15 signaling may prove to be a new, even durable, treatment strategy. Ongoing research seeks to better characterize the mechanism of action of these new treatments and to identify new targets in order to design an optimal therapeutic strategy for vitiligo patients. Long-term goals are to bring new treatments with better safety and efficacy into the clinic and ultimately to find a cure for this psychologically devastating disease.